Article

John Theurer Cancer Center Launches Podcast Series

Author(s):

The John Theurer Cancer Center (JTCC) at Hackensack University Medical Center today announced the launch of "JTCC: The Future of Cancer Care," a podcast series featuring in-depth conversations with clinicians and researchers.

The John Theurer Cancer Center (JTCC) at Hackensack University Medical Center today announced the launch of "JTCC: The Future of Cancer Care," a podcast series featuring in-depth conversations with clinicians and researchers whose pioneering efforts have placed JTCC among the world's leading cancer research and treatment centers.

Available on Apple's iTunes, "JTCC: The Future of Cancer Care" features interviews with leading JTCC physicians who collectively have been responsible for many of the clinical and research advancements in the treatment of hematologic and solid tumors, including leukemias, lymphomas, myelomas, and breast, gynecologic and head and neck cancers.

JTCC physicians have also been responsible for a quarter-century of clinical innovation in the use of bone marrow transplantation (BMT) for the treatment of life-threatening hematologic malignancies. In December 2015, the Center commemorated the 25th anniversary of its first BMT. To date, JTCC physicians have performed nearly 6,000 BMTs.

The most recent podcast was posted on February 18, 2016, and features Stefan Faderl, M.D., chief of JTCC's Leukemia Division, highlighting his perspectives on patient care, clinical trials and holistic care.

The podcast is consistently ranked among the top 5 in iTunes' science and medicine category. "JTCC: The Future of Cancer Care" may be accessed through iTunes via https://itunes.apple.com/us/podcast/the-future-of-cancer-care/id1080332763?mt=2.

"Over the past 25 years, JTCC has been at the forefront of discovery and treatment of some of the most complex cases. This podcast series is an important channel to highlight the groundbreaking work of our dedicated team of clinical and research professionals for physicians and patients alike," said Andre M. Goy, M.D., M.S., Chairman and Director, Lymphoma Division Chief, Chief Science Officer and Director of Research and Innovation, Regional Cancer Care Associates. "We are at a tipping point in cancer research and treatment because of our understanding of cancer cell biology; two-thirds of the pipeline in medicine is for cancer medicines."

The podcast series premiered on February 2, 2016, with Andrew M. Pecora, M.D., Chief Innovation Officer, Professor and Vice President of Cancer Services at JTCC, discussing cancer care innovation, outcomes, models of care and the future of personalized treatment.

"We believe that education and access to information go hand-in-hand with clinical and research excellence," said Dr. Pecora. "Healthcare providers and patients alike need and expect information that enables the best treatment choices. Our hope is that this podcast series can play a role in providing important and timely insights that expand patient understanding and help physicians deliver the best possible care."

About John Theurer Cancer Center at Hackensack University Medical Center

John Theurer Cancer Center is New Jersey's largest and most comprehensive cancer center dedicated to the diagnosis, treatment, management, research, screenings, preventive care, as well as survivorship of patients with all types of cancer.

Each year, more people in the New Jersey/New York metropolitan area turn to John Theurer Cancer Center for cancer care than to any other facility in New Jersey. The 14 specialized divisions feature a team of medical, research, nursing and support staff with specialized expertise that translates into more advanced, focused care for all patients. John Theurer Cancer Center provides comprehensive multidisciplinary care, state of the art technology, and access to clinical trials, compassionate care and medical expertise— all under one roof. Physicians at John Theurer Cancer Center are members of Regional Cancer Care Associates, one of the nation's largest professional hematology/oncology groups. For more information please visit www.jtcancercenter.org.

Related Videos
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss long-term data for CPX-351 in acute myeloid leukemia.
James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss factors to help determine intensive chemotherapy fitness in acute myeloid leukemia.
James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss the diagnosis and prevalence of secondary acute myeloid leukemia.
David Samuel Dicapua Siegel, MD
Noa Biran, MD
Noa Biran, MD